-
Product Insights
AP Thailand – Aspire Pinklao Arun Amarin Condominium Development – Bangkok
Equip yourself with the essential tools needed to make informed and profitable decisions with our AP Thailand - Aspire Pinklao Arun Amarin Condominium Development - Bangkok report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Company Profile
NewAmarin Corp Plc – Company Profile
Amarin Corp Plc (Amarin) is a pharmaceutical company which develops and commercializes medicines for cardiovascular diseases. The company's lead product, Vascepa (icosapent ethyl), is a single-molecule prescription capsule used as an adjunct to diet for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia andcardiovascular risk. Amarin is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. The company markets...
Add to Basket -
Thematic Analysis
Social Responsibility Trends in Healthcare – Thematic Intelligence
This report analyzes the impact of social responsibility pressures on the Healthcare sector. Who Should Buy Senior executives and ESG executives in Healthcare industry.
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Product Insights
Net Present Value Model: Vascepa
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vascepa Drug Details Icosapent ethyl (Vascepa,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – icosapent ethyl
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry icosapent ethyl Drug Details Icosapent ethyl (Vascepa, Vazkepa) is a synthetic derivative of the...
-
Product Insights
Myasthenia Gravis Disease – Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Myasthenia Gravis Clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Product Insights
Myasthenia Gravis Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H2, 2020" provides an overview of Myasthenia Gravis Clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...